FI971420A0 - Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä - Google Patents
Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämälläInfo
- Publication number
- FI971420A0 FI971420A0 FI971420A FI971420A FI971420A0 FI 971420 A0 FI971420 A0 FI 971420A0 FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 A0 FI971420 A0 FI 971420A0
- Authority
- FI
- Finland
- Prior art keywords
- kgf
- procedure
- treatment
- diabetes mellitus
- mammals
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32334094A | 1994-10-13 | 1994-10-13 | |
| US32347594A | 1994-10-13 | 1994-10-13 | |
| US48782595A | 1995-06-07 | 1995-06-07 | |
| PCT/IB1995/000992 WO1996011950A1 (en) | 1994-10-13 | 1995-10-12 | Method of treating diabetes mellitus using kgf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI971420L FI971420L (fi) | 1997-04-04 |
| FI971420A0 true FI971420A0 (fi) | 1997-04-04 |
| FI971420A7 FI971420A7 (fi) | 1997-04-04 |
Family
ID=27406268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI971420A FI971420A7 (fi) | 1994-10-13 | 1995-10-12 | Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä |
| FI971536A FI120040B (fi) | 1994-10-13 | 1997-04-11 | Keratinosyytti-kasvutekijän analogeja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI971536A FI120040B (fi) | 1994-10-13 | 1997-04-11 | Keratinosyytti-kasvutekijän analogeja |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0804479B1 (cs) |
| JP (2) | JP4216329B2 (cs) |
| KR (1) | KR100278597B1 (cs) |
| CN (1) | CN1168678A (cs) |
| AT (2) | ATE237633T1 (cs) |
| AU (1) | AU3707795A (cs) |
| BG (2) | BG101392A (cs) |
| BR (2) | BR9509329A (cs) |
| CA (2) | CA2202075C (cs) |
| CZ (3) | CZ297328B6 (cs) |
| DE (2) | DE69535264T2 (cs) |
| DK (2) | DK0785948T3 (cs) |
| EE (2) | EE03975B1 (cs) |
| ES (2) | ES2196082T3 (cs) |
| FI (2) | FI971420A7 (cs) |
| HU (2) | HU226168B1 (cs) |
| NO (2) | NO318761B1 (cs) |
| NZ (2) | NZ505502A (cs) |
| PL (2) | PL182888B1 (cs) |
| PT (2) | PT804479E (cs) |
| SI (2) | SI0785948T1 (cs) |
| SK (2) | SK43197A3 (cs) |
| WO (2) | WO1996011949A2 (cs) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008771A1 (en) | 1989-01-31 | 1990-08-09 | Rubin Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| DE122006000005I2 (de) | 1993-06-29 | 2006-11-23 | Chiron Corp | Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t |
| US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| CZ98297A3 (cs) * | 1994-10-13 | 1998-08-12 | Amgen Inc. | Způsob purifikace keratinocytových růstových faktorů |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| DE69603269T3 (de) * | 1995-04-27 | 2007-02-22 | Coöperatie Cosun U.A. | Derivate von inulin |
| AU727678C (en) * | 1996-10-15 | 2005-05-12 | Biovitrum Ab (Publ) | Keratinocyte growth factor-2 products |
| EP1473366A1 (en) * | 1996-10-15 | 2004-11-03 | Amgen Inc. | Keratinocyte growth factor-2 products |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| CN1283997A (zh) | 1997-12-22 | 2001-02-14 | 人类基因组科学公司 | 角质形成细胞生长因子－2制剂 |
| US6242666B1 (en) * | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
| ES2373093T3 (es) * | 1999-01-14 | 2012-01-31 | Bolder Biotechnology, Inc. | Métodos para preparar proteínas que contienen restos de cisteína libres. |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US6248725B1 (en) | 1999-02-23 | 2001-06-19 | Amgen, Inc. | Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction |
| WO2002062842A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
| JP2005500390A (ja) * | 2001-08-21 | 2005-01-06 | カイロン コーポレイション | Ｋｇｆポリペプチド組成物 |
| AU2007214362B2 (en) * | 2001-08-21 | 2009-11-26 | Novartis Vaccines And Diagnostics, Inc. | KGF polypeptide compositions |
| EP1827483B1 (en) | 2004-12-15 | 2014-07-02 | Swedish Orphan Biovitrum AB (publ) | Therapeutic formulations of keratinocyte growth factor |
| CN102242124B (zh) * | 2010-05-10 | 2013-05-22 | 齐鲁制药有限公司 | 改造的角化细胞生长因子基因及其在酵母中的表达 |
| KR102440312B1 (ko) * | 2020-08-28 | 2022-09-05 | 한국해양과학기술원 | 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| JPH01137994A (ja) * | 1987-08-10 | 1989-05-30 | Shionogi & Co Ltd | ｒｅｇ蛋白質 |
| WO1990000877A1 (en) * | 1988-07-27 | 1990-02-08 | Marjan International Pty Ltd | Carpet stretcher |
| WO1990008771A1 (en) * | 1989-01-31 | 1990-08-09 | Rubin Jeffrey S | Dna encoding a growth factor specific for epithelial cells |
| JP3303211B2 (ja) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | ｂＦＧＦムテインおよびその製造法 |
| IL109122A (en) * | 1993-03-26 | 2004-07-25 | Amgen Inc | Use of keratinocyte growth factor products to prepare pharmaceutical compositions |
| US5348563A (en) * | 1993-06-29 | 1994-09-20 | Honeywell Inc. | Air purifying apparatus |
| DE122006000005I2 (de) * | 1993-06-29 | 2006-11-23 | Chiron Corp | Verk}rzter Keratinocytenwachstumsfaktor (kgf) mit erh¦hter Biologischer aktivit{t |
| GB9315501D0 (en) * | 1993-07-27 | 1993-09-08 | Ici Plc | Surfactant compositions |
| EP0712314A1 (en) * | 1993-08-02 | 1996-05-22 | Prizm Pharmaceuticals, Inc. | Monogenous preparations of cytotoxic conjugates |
-
1995
- 1995-10-12 CN CN95196410A patent/CN1168678A/zh active Pending
- 1995-10-12 PT PT95934808T patent/PT804479E/pt unknown
- 1995-10-12 EP EP95934808A patent/EP0804479B1/en not_active Expired - Lifetime
- 1995-10-12 SI SI9530654T patent/SI0785948T1/xx unknown
- 1995-10-12 DK DK95934793T patent/DK0785948T3/da active
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/cs not_active IP Right Cessation
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en not_active Ceased
- 1995-10-12 DE DE69535264T patent/DE69535264T2/de not_active Expired - Lifetime
- 1995-10-12 HU HU9901255A patent/HU226168B1/hu not_active IP Right Cessation
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/ko not_active Expired - Fee Related
- 1995-10-12 SK SK431-97A patent/SK43197A3/sk unknown
- 1995-10-12 SI SI9530728T patent/SI0804479T1/sl unknown
- 1995-10-12 ES ES95934793T patent/ES2196082T3/es not_active Expired - Lifetime
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
- 1995-10-12 BR BR9509329A patent/BR9509329A/pt not_active Application Discontinuation
- 1995-10-12 JP JP51307796A patent/JP4216329B2/ja not_active Expired - Fee Related
- 1995-10-12 SK SK455-97A patent/SK284534B6/sk not_active IP Right Cessation
- 1995-10-12 EP EP95934793A patent/EP0785948B1/en not_active Expired - Lifetime
- 1995-10-12 BR BR9509269A patent/BR9509269A/pt not_active Application Discontinuation
- 1995-10-12 AT AT95934793T patent/ATE237633T1/de active
- 1995-10-12 FI FI971420A patent/FI971420A7/fi unknown
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/cs not_active IP Right Cessation
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/cs unknown
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 PL PL95319784A patent/PL182888B1/pl not_active IP Right Cessation
- 1995-10-12 EE EE9700081A patent/EE03975B1/xx not_active IP Right Cessation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/ja not_active Expired - Fee Related
- 1995-10-12 DK DK95934808T patent/DK0804479T3/da active
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en not_active Ceased
- 1995-10-12 PL PL95320484A patent/PL320484A1/xx unknown
- 1995-10-12 ES ES95934808T patent/ES2273338T3/es not_active Expired - Lifetime
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 EE EE9700225A patent/EE9700225A/xx unknown
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
- 1995-10-12 PT PT95934793T patent/PT785948E/pt unknown
- 1995-10-12 AT AT95934808T patent/ATE342278T1/de active
- 1995-10-12 HU HU9901071A patent/HUT78050A/hu unknown
- 1995-10-12 DE DE69530403T patent/DE69530403T2/de not_active Expired - Lifetime
-
1997
- 1997-04-04 NO NO19971568A patent/NO318761B1/no not_active IP Right Cessation
- 1997-04-04 NO NO971566A patent/NO971566L/no unknown
- 1997-04-07 BG BG101392A patent/BG101392A/xx unknown
- 1997-04-11 FI FI971536A patent/FI120040B/fi not_active IP Right Cessation
- 1997-04-11 BG BG101408A patent/BG63167B1/bg unknown
-
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI971420A0 (fi) | Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä | |
| UA56989C2 (uk) | ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ | |
| DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
| MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
| ATE218350T1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| AU2899889A (en) | Novel method | |
| ATE234615T1 (de) | Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren | |
| AU5323396A (en) | Methods of treating inflammation and compositions therefor | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| DE69509318D1 (de) | Hyperbarische Druckkammer für medizinische Hochdruck Behandlung mit keinen strukturellen Hindernissen | |
| DE69113773D1 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
| NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
| AUPM836794A0 (en) | Improved method and composition for the treatment of ulcers | |
| UA28288A (uk) | Спосіб лікування шизофренії | |
| ATE315583T1 (de) | Analoge des thymosin alpha 1 | |
| ATE318612T1 (de) | Methoden und zusammensetzungen zur behandlung der hyperlipidämie | |
| MX9605327A (es) | Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis. | |
| UA15363A (uk) | Засіб для лікуваhhя відкритих пошкоджеhь | |
| AU3597695A (en) | Improved method and composition for the treatment of ulcers |